RTP-based G1 Therapeutics files for $115M IPO
Related Blog Posts
- Inside an IPO offering: G1 Therapeutics lays out its case for investors
- New G1 Therapeutics trials target breast cancer
- Eshelman-backed G1, Genetech to test combo cancer therapy
- G1 Therapeutics adds another $3M to latest funding round
- RTP's G1 Therapeutics begins clinical trials of chemoprotectant in lung cancer patients
- G1 Therapeutics lands $33 million, Eshelman as investor
- Venture-backed startup G1 Therapeutics names CEO
On The Web
Research Triangle Park, N.C. — G1 Therapeutics Inc., a clinical-stage biopharmaceutical company based in the Research Triangle Park, filed Thursday for an initial public offering of $115 million.
G1 Therapeutics focuses on the discovery and development of novel therapeutics for the treatment of cancer. It plans to use proceeds from the offering to advance the development of its trilaciclib, G1T38 and G1T48 drugs.
G1 Therapeutics is believed to be the only company with two distinct clinical-stage CDK4/6 inhibitors, trilaciclib and G1T38, each of which has the potential to be the foundation of multiple regimens.
- WTW INSIDER: INSIDE THE IPO: G1 makes its pitch to investors
The company reported a net loss of $30.3 million in 2016, a 49 percent increase from its net loss of $20.3 million in 2015. The company reported an accumulated deficit of $65 million as of Dec. 31, 2016.
G1 Therapeutics reported that its net losses have resulted from costs incurred in connection with its research and development programs and from general expenses associated with its operations.
The company has received all of its revenue to date from government grants.
J.P. Morgan Securities LLC, Cowen and Company LLC, Needham & Company LLC and Wedbush Securities Inc. are underwriting the offering.
The filing lists the company’s book value per share before the offering as negative $14.49 per share, with a book value of $0.70 after going public.
Mark Velleca has served as G1 Therapeutics’ president and CEO since May 2014. Prior to G1, Velleca was a co-founder and the senior vice president of CGI Pharmaceuticals Inc., a biopharmaceutical company, from 1999 to 2010.
Velleca’s total compensation for 2016 was $1,334,796. He received a base salary of $405,000 and $788,196 in option awards.
Note: This story is from the North Carolina Business News Wire, a service of UNC-Chapel Hill’s School of Media and Journalism
Please Log In to add a comment.
Latest for Insiders
- Dr. James Goodnight: From moment of inspiration to building SAS, a global software powerhouse
- With all tickets gone, TechWire Awards to be streamed live at WRAL.com
- As Scot Wingo's new gig Spiffy lands extra $2.5M, he 'loves' being back with a startup
- Dr. Charles Hamner: A creator of NC's life science industry
- First WRAL TechWire Hall of Famers: Five pillars of NC's tech success
- Why Red Hat's new CFO left IBM - and what he likes better
- Eric Shander's journey: From IBM to Red Hat, chief accounting officer to CFO
- Datathon at Duke offers big talent recruiting opportunity, says former Red Hat exec
- 'Life is more than self'- The driver for 2017 WRAL TechWire awards
- SEC's big 'fake news' crackdown shows a major threat to readers, investors